Candel Therapeutics Inc. (CADL)
| Bid | 5.07 |
| Market Cap | 258.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.58M |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | -3.88 |
| Forward PE | -3.98 |
| Analyst | Buy |
| Ask | 5.55 |
| Volume | 657,637 |
| Avg. Volume (20D) | 996,774 |
| Open | 5.18 |
| Previous Close | 5.13 |
| Day's Range | 5.12 - 5.33 |
| 52-Week Range | 3.79 - 14.60 |
| Beta | -0.87 |
About CADL
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for CADL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 weeks ago · proactiveinvestors.com
Candel Therapeutics get FDA's RMAT designation for prostate cancer therapyCandel Therapeutics Inc (NASDAQ:CADL) said on Wednesday the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate, C...
3 weeks ago · proactiveinvestors.com
Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025Candel Therapeutics Inc (NASDAQ:CADL) announced that it will present results from its positive Phase 3 trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer at the 202...
1 month ago · proactiveinvestors.com
Candel Therapeutics posts Q1 profit, eyes 2026 BLA submission for prostate cancer drugCandel Therapeutics Inc (NASDAQ:CADL) reported a quarterly profit and said it remains on track to submit a biologics license application (BLA) in late 2026 for its lead cancer therapy, CAN-2409, aimed...
2 months ago · proactiveinvestors.com
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409Candel Therapeutics Inc (NASDAQ:CADL) shared promising results from a Phase 1b clinical trial testing its experimental cancer therapy, CAN-2409, in patients with newly diagnosed high-grade glioma—a pa...